000876:SZSENew Hope Liuhe Co.,Ltd. Analysis
Data as of 2026-03-17 - not real-time
CN¥8.79
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
New Hope Liuhe is trading at a trailing PE of about 40 and a price‑to‑book of 2.1, suggesting the market is pricing in a premium despite modest 4.5% revenue growth and thin profit margins (1% net margin). The balance sheet is heavily leveraged, with a debt‑to‑equity ratio north of 169, which limits financial flexibility and raises concerns about dividend sustainability. Technical signals show the stock price (8.79 CNY) sitting below the 20‑day (8.75) and 50‑day (8.88) moving averages, and the longer‑term 200‑day SMA (9.48) remains a barrier, indicating a bearish bias. However, the MACD histogram turned positive and the signal line is bullish, hinting at a possible short‑term bounce near the current support around 8.56. Volatility over the past month is around 17.6% while beta is exceptionally low (0.14), meaning price swings are pronounced but largely independent of broader market moves. The dividend yield is a paltry 0.27% with a payout ratio of only about 11%, which may not be attractive given the high leverage. Overall, the stock faces a mix of valuation pressure, debt risk, and limited upside, making a cautious stance prudent.
Given the current technical layout and fundamental constraints, the near‑term outlook leans toward a hold with a watchful eye on any earnings or debt‑restructuring news. Medium‑term expectations remain muted as growth prospects are modest and the cost structure is tight; investors should monitor cash‑flow generation against debt service needs. Over the longer horizon, the combination of high leverage, low returns on equity (3.2%) and a relatively expensive valuation suggests a potential downgrade to a sell recommendation unless the company can meaningfully improve profitability or deleverage its balance sheet.
Given the current technical layout and fundamental constraints, the near‑term outlook leans toward a hold with a watchful eye on any earnings or debt‑restructuring news. Medium‑term expectations remain muted as growth prospects are modest and the cost structure is tight; investors should monitor cash‑flow generation against debt service needs. Over the longer horizon, the combination of high leverage, low returns on equity (3.2%) and a relatively expensive valuation suggests a potential downgrade to a sell recommendation unless the company can meaningfully improve profitability or deleverage its balance sheet.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price below short‑term moving averages
- Positive MACD histogram suggests limited upside
- Support level near 8.56 CNY
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Modest revenue growth of 4.5%
- High debt‑to‑equity ratio limiting flexibility
- Valuation still near historical averages
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Debt burden (D/E > 160) and low ROE
- Elevated PE (~40) relative to earnings growth
- Weak dividend yield and sustainability concerns
Key Metrics & Analysis
Financial Health
Revenue Growth4.50%
Profit Margin1.02%
P/E Ratio40.0
ROE3.25%
ROA1.55%
Debt/Equity169.38
P/B Ratio2.1
Op. Cash FlowCN¥8.7B
Free Cash FlowCN¥1.2B
Technical Analysis
TrendBearish
RSI48.5
SupportCN¥8.56
ResistanceCN¥9.04
MA 20CN¥8.75
MA 50CN¥8.88
MA 200CN¥9.48
MACDBullish
VolumeIncreasing
Fear & Greed Index81.43
Valuation
Target PriceCN¥8.70
Upside/Downside-1.02%
GradeFair
TypeBlend
Dividend Yield0.27%
Risk Assessment
Beta0.14
Volatility17.63%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.